share_log

中源协和(600645.SH):VUM02注射液药品临床试验申请取得受理通知书

vcanbio cell & gene engineering corp.,ltd. (600645.SH): Received notice of acceptance for clinical trial application of pharmaceutical VUM02 injection.

Gelonghui Finance ·  Jun 20 05:31

On June 20, Gelunhui reported that its wholly-owned subsidiary, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., recently obtained the "Acceptance Notice" for the clinical trial application for the new indication of VUM02 injection issued by the Drug Evaluation Center (CDE) of the National Medical Products Administration. VUM02 injection (human umbilical cord mesenchymal stem cell injection) is a freeze-dried stem cell preparation independently developed by our company. The new drug is prepared from screened healthy newborn umbilical cord tissue through in vitro separation, amplification, harvesting, cryopreservation, and isolation of human umbilical cord mesenchymal stem cells (UC-MSCs), and is clinically intended to treat systemic sclerosis.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment